Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
6 competitors in Advanced Solid Tumor
No patent data available. Pre-approval drugs may not have Orange Book listings.
Fruzaqla
Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF agents, and anti EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine tipiracil or regorafenib.
View on EMAAcute Myeloid Leukemia
Metastatic Pancreatic Cancer
Advanced Renal Cell Carcinoma
Advanced Intrahepatic Cholangiocarcinoma
Advanced Endometrial Cancer